Androgens in aging men: Do men benefit from testosterone replacement?

Journal of Anti-Aging Medicine

Volumn 1, Issue 4, 1998, Pages 359-364

  Bagatell, Carrie J ^a   Bremner, William J ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0012645276     PISSN: 10945458     EISSN: None     Source Type: Journal    
DOI: 10.1089/rej.1.1998.1.359     Document Type: Article

References (47)

1. Gray, A, Beeline JA, McKinlay JB, et al.: An examination of research design effects on the association of testosterone and male aging: The results of a meta-analysis. J Clin Epidemiol 1991;44:671-684.
2. Tenover JS: Androgen administration to aging men. Endocrinol Metab Clin North Am 1994;23:877-892.
3. Tsitoura P, Bulat T: The aging male reproductive system. Endocrinol Metab Clin North Am 1995;24:295-315.
4. Bremner WJ, Vitiello MV, Prinz PN: A loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab 1983;56: 1278-1281.
5. Vermeulen A, Deslypere J: Testicular endocrine function in the aging male. Maturitas 1985;7:273-279.
6. Plymate SR, Tenover JS, Bremner WJ: Circadian variation in testosterone, sex hormone binding globulin, and calculated non-sex hormone binding globulin bound testosterone in healthy young and elderly men. J Androl 1989;10:366-371.
7. Morley JE, Kaiser FE, Perry HM, et al.: Longitudinal changes in testosterone, luteinizing hormone, and follicle stimulating hormone in healthy older men. Metabolism 1997;46:410-413.
8. Sih R, Morley JE, Kaiser FE, et al.: Testosterone replacement in older hypogonadal men: A 12-month randomized controlled trial. J Clin Endocrinol Metab 1997;82:1661-1667.
9. Tenover JS: Androgen therapy in aging men. In: Bhasin S, Gabelnick HL, Spieler JM (eds.): Pharmacology, Biology and Clinical Applications of Androgens. New York: Wiley-Liss, 1996:309-318.
10. Mooradian AD, Morley JE, Korenman SG: Biological effects of androgens. Endocr Rev 1987;7:1-28.
11. Bagatell CJ, Bremner WJ: Androgens in men: Uses and abuses. N Engl J Med 1996;334:707-714.
12. Forbes, GB, Reina JC: Adult lean body mass declines with age: Some longitudinal observations. Metabolism 1970;19:653-663.
13. Katznelson L, Finkelstein JS, Schoenfeld DA, et al.: Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996;81:4358-4365.
14. Bhasin S, Storer TW, Berman N, et al.: The effects of supraphysiological doses of testosterone on muscle size and strength in men. N Engl J Med 1996;335:1-7.
15. Bagatell CJ, Heiman JR, Rivier JE, et al.: Effects of endogenous testosterone and estradiol on sexual behavior in normal young men. J Clin Endocrinol Metab 1994;77:711-716.
16. Davidson JM, Camargo CA, Smith E: Effects of androgen on sexual behavior in hypogonadal men. J Clin Endocrinol Metab 1979;48:955-958.
17. O'Carroll R, Shapiro C, Bancroft J: Androgens, behaviour, and nocturnal erection in hypogonadal men: The effects of varying the replacement dose. Clin Endocrinol (Oxf) 1985;23:527-538.
18. Davidson JM, Chen JJ, Crapo L, et al.: Hormonal changes and sexual function in aging men. J Clin Endocrinol Metab 1983;57:71-77.
19. Jackson JA, Kleerekoper M: Osteoporosis in men: Diagnosis, pathophysiology, prevention. Medicine 1990;69:137-152.
20. Goldray D, Weisman Y, Jaccard N, et al.: Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Trp6-GnRH). J Clin Endocrinol Metab 1993;76: 288-290.
21. Finkelstein JS, Klibanski A, Neer RM, et al.: Osteoporosis in men with idiopathic hypothalamic hypogonadism. Ann Intern Med 1987;106:354-361.
22. Finkelstein JS, Neer RM, Biller BMK, et al.: Osteopenia in adult men with delayed puberty. N Engl J Med 1992;326:600-604.
23. Hajjar R, Kaiser FE, Morley JE: Outcomes of long-term testosterone replacement in older hypogonadal males: A retrospective analysis. J Clin Endocrinol Metab 1997;82:3793-3796.
24. Tenover JS: Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992;75: 1092-1098.
25. Janowsky JS, Oviatt SK, Orwoll ES: Testosterone administration enhances spatial cognition in older men. Behav Neurosci 1994;108:325-332.
26. Morley JE, Perry M, Kaiser FE, et al.: Effects of testosterone replacement therapy in older hypogonadal males: A preliminary study. J Am Geriatr Soc 1993;41L: 149-152.
27. Bhasin S, Tenover JS: Age associated sarcopenia-issues in the use of testosterone as an anabolic agent in older men [Editorial]. J Clin Endocrinol Metab 1997;82: 1659-1660.
28. Marin P, Holmang S, Gustafsson C, et al.: Androgen treatment of abdominally obese men. Obes Res 1993; 245-251.
29. Orwoll E, Oviatt S, Deftos L, et al.: Transdermal testosterone supplementation in normal men: Effects on bone and mineral metabolism. J Bone Miner Res 1992;7:s321.
30. Kirkland RT, Keenan BS, Probstfield JL, et al.: Decrease in plasma high-density lipoprotein cholesterol levels at puberty in boys with delayed adolescence. JAMA 1987;257:502-507.
31. Sorva R, Kuusi T, Taskinen MR, et al.: Testosterone substitution increases the activity of lipoprotein lipase and hepatic lipase in hypogonadal males. Atherosclerosis 1988;69:191-197.
32. Thompson PD, Cullinane EM, Sady SP, et al.: Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA 1989;261:1165-1168.
33. Bagatell CJ, Heiman JR, Matsumoto AM, et al.: Metabolic and behavioral effects of high dose, exogenous testosterone (T) in normal men. J Clin Endocrinol Metab 1994;79:561-567.
34. Meriggiola MC, Marcovina S, Paulsen CA, et al.: Testosterone enanthate at the dose of 200 mg/week decreases HDL-cholesterol levels in healthy men. Int J Androl 1995;18:237-242.
35. Marcovina SM, Lippi G, Bagatell CJ, et al.: Testosterone induced suppression of lipoprotein (a) in normal men: Relation to basal lipoprotein (a) level. Atherosclerosis 1996;122:89-95.
36. Zmuda JM, Thompson PD, Dickenson R, et al.: Testosterone decreases lipoprotein (a) in men. Am J Cardiol 1996;77:122-124.
37. Marin P, Holmang S, Johsson L, et al.: The effect of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord 1992;16:991-997.
38. Peiris AN, Sothmann MS, Hoffmann RG, et al.: Adiposity, fat distribution, and cardiovascular risk. Ann Intern Med 1989;110:867-872.
39. Cunningham GR: Overview of androgens on the normal and abnormal prostate. In: Bhasin S, Gabelnick HL, Spieler JM (eds.). Pharmacology, Biology and Clinical Applications of Androgens. New York: Wiley-Liss, 79-93.
40. Eri LM, Tveter KJ: A prospective, placebo controlled study of the luteinizing hormone releasing hormone antagonist, leuprolide, as treatment for patients with benign prostatic hyperplasia. J Urol 1993;150:359-364.
41. Behre HM, Bohmeyer J, Neischlag E: Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. J Clin Endocrinol 1994;40:341-349.
42. Morgantaler A, Bruning CO, DeWolf WC: Occult prostate cancer in men with low serum testosterone levels. JAMA 1996;276:1904-1906.
43. Bagatell CJ, Matsumoto AM, Christensen RB, et al.: Comparison of a gonadotropin releasing hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens. J Clin Endocrinol Metab 1993;77:427-432.
44. Bebb RA, Anawalt BD, Christensen RB, et al.: Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: A promising male contraceptive approach. J Clin Endocrinol Metab 1996;81:757-762.
45. Arver S, Meikle AW, Dobs AS, et al.: Hypogonadal men treated with the Androderm testosterone transdermal system had fewer abnormal hematocrit elevations than those treated with testosterone enanthate injections. Program of the 79th meeting of the Endocrine Society, Minneapolis, MN, 1997:216.
46. Ishak KG, Zimmerman HJ: Hepatotoxic effects of the anabolic/androgenic steroids. Semin Liver Dis 1987;7: 230-236.
47. Cummings DE, Kumar N, Bardin CW, et al.: Prostate-sparing effects in primates of the potent androgen 7α-methyl-19-nortestosterone. J Clin Endoc Metab 1998;83: (in press).